A European working group has provided a new set of recommendations for the use of cerebrospinal fluid (CSF) biomarkers in the diagnostic evaluation of Alzheimer disease and mild cognitive impairment. These recommendations represent an important step towards the implementation of CSF biomarker tests in the clinic, but several challenges remain.